When most people try to lose weight, they watch one number: the scale. But not all weight loss is...
Belviq (Lorcaserin) is the Newest Tool for Weight Loss
By: Scottsdale Weight Loss Center
Published: May 7, 2013
Please Don’t Drink Your Calories if You’re Focused on Weight Loss
Liquid calories are fluids consumed as part of your daily diet that often go unnoticed and...
Rock Climbing: Lose Weight on the Wall
If your weight loss efforts have hit a wall, why not climb it? Rock climbing is becoming an...
Weight Watchers vs. Medical Weight Loss Programs in Scottsdale: Comparing the Results
Many residents in Scottsdale, Phoenix, and Glendale struggle with weight loss plateaus despite...
Arizona Medical Weight Loss Programs vs Online Programs: Which One Provides the Best Results?
The weight loss landscape has shifted significantly with the rise of digital health platforms....
Is Brown Rice Healthier Than White Rice?
Is brown rice better than white rice? Intuitively, one would think that brown rice is much...
It’s an exciting time to be in weight loss. The FDA recently approved 2 new drugs for weight loss. The first to be approved was Belviq (lorcaserin) (Arena Pharmaceuticals) and the second approved was Qsymia (Phentermine/Topiramate ER) (Vivus, Inc.).
Belviq/Lorcaserin
Lorcaserin is a selective serotonin 2C agonist that decreases the intake of food. The last serotonin agonist used for weight loss, fenfluramine, was nonspecific and, unfortunately, also stimulated the serotonin 2B receptors expressed on cardiac valves. This stimulation is thought to have thickened the leaflets and chordae tendineae of the cardiac valves leading to damage and cardiac fibrosis. Fenfluramine was taken off of the market in 1997. Lorcaserin is 100 times more specific for the 2C receptors than the 2B receptors.
The Studies.
The first study to be published supporting lorcaserin was called Behavioral Modification and Lorcaserin for Overweight and Obesity Management or BLOOM.[1] In this trial, patients with body mass indices (BMIs) of 30 to 45kg/m2 or 27 to 45kg/m2 with a least one obesity-related comorbidity were enrolled. Patients with pre-existing valvulopathy, persistently elevated blood pressure, pregnancy, or diabetes were excluded. In this trial, 3,182 patients in a double-blind fashion were randomly assigned to receive either lorcaserin 10mg twice daily (BID) or placebo BID for 52 weeks.
In the lorcaserin group, 47.5 percent of patients lost five percent or more of their body weight with an average weight loss of 5.8±0.2kg. In the placebo group, 20.3 percent of patients lost five percent or more of their body weight with an average weight loss of 2.2±0.1kg.
Additionally, weight was maintained in more patients who continued to use lorcaserin (67.9%) than placebo (50.3%). Among the 2,472 patients evaluated at Year 1 and 1,127 patients evaluated at Year 2, the rate of cardiac valvulopathy was not increased with use of lorcaserin (Lorcaserin group 2.7% and placebo 2.3%).
In the second study, the Behavioral Modification and Lorcaserin Second Study for Obesity Management or Blossom,[2] 4,008 patients with BMIs of 30 to 65kg/m2 or 27 to 29.9kg/m2 with one obesity-related comorbidity were randomly assigned to one of the following three groups: 1) lorcaserin 10mg BID, 2) lorcaserin 10mg once daily (QD), or 3) placebo. Patients taking lorcaserin who lost at least five percent of their baseline weight was achieved as follows: lorcaserin 10mg BID, 22.6 percent; lorcaserin 10mg QD, 17.4 percent; and placebo, 9.7 percent.
Patients with recent cardiovascular events, diabetes, or those who had taken selective serotonin reuptake inhibitors (SSRIs) in the past year were excluded. Patients who discontinued the study citing lack of efficacy as the reason were 2.4% in the higher dose, 3.1% in the lower dose, and 3.9% in the placebo group, respectively. Dropouts due to adverse events were 7.2, 6.2, and 4.6 percent in the three groups, respectively. Adverse events included headache, upper respiratory infection, nausea, dizziness, and fatigue. Adverse events occurred in 82.6, 81.5, and 75.3 percent of patients, respectively.
Using a modified intention-to-treat-last-observation-carried-forward analysis, patients taking Lorcaserin lost an average of 5.8kg at 52 weeks, which was 2.9kg more than patients on placebo.
Summary
It’s still early in the game for both Belviq and Qsymia. Time will determine the final clinical utility of these drugs and the best uses for them. As of now, we should be excited about these new options being made available to our patients and the future of medical obesity treatment.
References
1. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of Lorcaserin for weight management. N Engl J Med. 2010;363:245–256.
2. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067–3077.
By Craig Primack, MD
Nick
Nick's Story
"I wish I would have come here first. We spend all our time reacting to the next great weight loss tip or program. It might work for a while, but does not last and we end up yo-yoing from one fad to the next – as we gain more weight." Read More
Gina
Lost 44.5 lbs
"I had no trouble adhering to the meals and they really helped catapult my progress! The classes were so beneficial to me because they helped change my thinking about how I viewed health, nutrition, and fitness.
I will always have my relationship with Scottsdale Weight Loss Center. They truly helped me change my life forever." Read More
Lauren
Lost 60 lbs
"Dr. Ziltzer and everyone who I have come in contact with at the Scottsdale Weight Loss office have been so encouraging and I look forward to seeing them each week. It is now a year and 2 months later since I started. I am down 60 lbs., which is the average amount a 9-year-old weighs, it is crazy to think I lost a whole person! I feel amazing, I hit my goal weight in November 2021 just before Thanksgiving. Nothing on my body hurts anymore..." Read More
Chuck
Lost 66 lbs
"The best thing I did was call the Scottsdale Weight Loss Center. I have a lot more energy, I'm not hungry, and it feels great.
You can take it from me that this is a program that produces results. The staff is always positive, supportive, and never judgmental.
Your visits always result in positive reinforcement, no matter if you had a good week or a bad week." Read More
Emily
Lost 101 lbs
"Here I am at the lowest I have been since high school weighing in at 155lbs. I have lost 101 lbs, BMI of 39 when I started, to 21.6, and of course at body fat % of 47.1 to 26.5%. I told myself by my 30th birthday I wanted to be confident in the way I look and I owe it all to SWLC. The entire staff is so welcoming and they are rooting for you just as much as you are rooting for yourself...." Read More
Reviews
Meet Our Team
Robert Ziltzer, MD, FACP, FAAP, FOMA
Obesity Medicine Certified Physician
Diana Bone, FNP-C
Specializing in Obesity Medicine
Craig Primack, MD, FACP, FAAP, MFOMA
Obesity Medicine Certified Physician
Kristen Ash, FNP-C, FNP-BC
Nurse Practitioner
Alicia Earley, FNP-C
Family Nurse Practitioner
